According to an announcement from Par, in Woodcliff Lake, the drug is indicated for the treatment of obsessive compulsive disorder. The company has been awarded 180 days of marketing exclusivity on its generic version.

According to IMS Health data cited in the release, annual U.S. sales of Luvox CR are approximately $51 million.